Torrid shut down 20 more locations in the first quarter of 2026, bringing the total number of stores closed under its "store optimization program" to 171 as the plus-size retailer tries to right-size a fleet battered by declining revenue and shifting consumer habits.
CEO Lisa Harper framed the closures as the final chapter of a deliberate strategy. But the numbers tell a harder story: net sales fell 7.6 percent in the first quarter, the company slashed prices on roughly a third of its merchandise, and nearly one in four American households now uses GLP-1 weight-loss medications, a trend the apparel industry itself calls a "structural change."
For shoppers who relied on Torrid as one of the few brick-and-mortar options for sizes 10 to 30, the math is simple. Fewer stores, fewer choices, and another familiar name retreating from the mall.
Torrid closed 151 locations last year. The 20 additional closures in the first quarter brought the cumulative total to 171 since the program began. Harper disclosed the figures during the company's Q1 2026 earnings call, as reported by The U.S. Sun.
The company did not identify which stores closed or where they were located. No specific cities, states, or malls were named in the earnings disclosure.
Harper characterized the shuttered locations as "structurally unproductive" and said the work is "now largely behind us":
"We have strategically rightsized our store fleet to one that is more productive, aligned and better positioned to serve our customer where and how she prefers to shop with us."
That language, "rightsized," "aligned," "positioned", is the corporate dialect companies reach for when the underlying reality is contraction. Torrid is not expanding. It is retreating to defensible ground.
Torrid is hardly the only mall tenant pulling back. JCPenney recently closed its Pittsburgh anchor store after nearly four decades, part of the same ongoing erosion that has hollowed out shopping centers across the country.
First-quarter net sales came in at $245.8 million. Harper called that "slightly above our guidance." Adjusted EBITDA hit $17.6 million, which she placed "at the high end of our guidance range."
But guidance is a bar a company sets for itself. The broader picture is less flattering. Net sales dropped 7.6 percent in the quarter. The company had already imposed price cuts on roughly a third of its stock, a move that props up volume but squeezes margins.
Harper tried to project optimism on the earnings call:
"These results reflect disciplined execution across our strategic initiatives and signal progress in positioning us for comparable sales growth in the back half of the year and beyond."
The promise of growth "in the back half" is a familiar refrain from retailers managing decline. Investors have heard it before.
The pattern extends well beyond Torrid. Fossil Group shut seven stores in its latest quarter as mall-based retailers continue to lose ground to online competition and changing consumer preferences.
One force working against Torrid has nothing to do with mall traffic or e-commerce. It has to do with pharmacy counters.
A March report from research firm Circana found that about 23 percent of all U.S. households were using GLP-1 medications to manage diabetes and weight as of September 2025, a 4 percent jump from 2024. That is nearly one in four households.
For a retailer whose entire brand identity is built around serving plus-size women, the implications are obvious. Kristen Classi-Zummo, an apparel industry adviser at Circana, described the shift in blunt terms:
"GLP-1 usage extends beyond the physical implications; it's a catalyst for redefining personal style. As consumers rebuild their wardrobes, they're reassessing what fits, what flatters, and what feels aligned with their lifestyle."
She went further, calling the trend a permanent realignment rather than a passing fad:
"Brands that plan for both the physical and emotional elements will lead. This isn't a trend, it's a structural change for the apparel industry."
A "structural change" for the apparel industry is a polite way of saying that Torrid's core customer base may be literally shrinking. If millions of women move from size 20 to size 14, they may not need a specialty retailer at all. They can walk into any department store.
Torrid's retreat fits a broader pattern that has accelerated in recent years. Mall anchors are disappearing. Mid-tier specialty chains are pulling leases. Traffic counts keep falling.
Even Apple, a company with no shortage of cash or brand loyalty, recently closed three stores in Connecticut, California, and Maryland because the malls housing them had deteriorated past the point of viability.
When a company worth trillions decides a mall location is no longer worth maintaining, it says something about the condition of the property itself. For a mid-cap retailer like Torrid, the calculus is even harsher. Every underperforming lease is dead weight on a balance sheet that cannot afford it.
The problem is not limited to any one region or category. Alabama's largest mall recently went up for sale after years of decline, a signal that the physical infrastructure of American retail is eroding beneath the stores that remain.
Harper said the company's "primary focus for 2026 is customer file growth through acquisition, reactivation, and retention." That is corporate-speak for: we need to find new customers, win back old ones, and keep the ones we have from leaving.
It is a reasonable strategy on paper. But it arrives at a moment when the company has fewer physical locations to attract walk-in traffic, a shrinking addressable market thanks to GLP-1 adoption, and a price-cutting posture that signals competitive pressure rather than brand strength.
The 171 store closures represent a significant share of what was once Torrid's physical footprint. The company has not disclosed how many locations remain open, and the earnings materials do not indicate whether additional closures are planned beyond the "substantially completed" program.
Harper's assertion that "that work is now largely behind us" leaves a hedge. "Largely" is not "entirely." And retailers that have gone through one round of optimization often find reasons for a second.
The broader retail landscape offers little comfort. Carter's recently announced plans to close 150 stores nationwide, another familiar chain that millions of families counted on finding at the local mall.
Corporate earnings calls treat store closures as line items, "optimization," "rightsizing," strategic repositioning. The language is designed to reassure investors, not the people who worked at those 171 locations or the customers who shopped there.
For women in smaller markets who relied on Torrid as one of the few places they could try on clothes in their size before buying, a closed store is not an optimization. It is one fewer option in a retail world that already offered them limited choices.
Torrid's leadership may be making the right financial calls. Closing money-losing stores is not irrational. Cutting prices to stay competitive is not reckless. But the trajectory, 171 closures, falling sales, a customer base reshaped by pharmaceutical innovation, raises a question the earnings call did not answer: what does the brand look like in three years if these trends continue?
When nearly a quarter of American households are on weight-loss drugs and your entire business model is built around serving the customers those drugs are designed to change, "optimization" may just be a polite word for managed retreat.